- Home
- ILPT vs HURA Comparison
ILPT vs HURA Comparison
Compare ILPT & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- HURA
- Stock Information
- Founded
- ILPT 2017
- HURA 2009
- Country
- ILPT United States
- HURA United States
- Employees
- ILPT N/A
- HURA N/A
- Industry
- ILPT Real Estate Investment Trusts
- HURA
- Sector
- ILPT Real Estate
- HURA
- Exchange
- ILPT Nasdaq
- HURA Nasdaq
- Market Cap
- ILPT 235.1M
- HURA 246.9M
- IPO Year
- ILPT 2018
- HURA N/A
- Fundamental
- Price
- ILPT $3.37
- HURA $4.39
- Analyst Decision
- ILPT Buy
- HURA
- Analyst Count
- ILPT 2
- HURA 0
- Target Price
- ILPT $10.00
- HURA N/A
- AVG Volume (30 Days)
- ILPT 351.3K
- HURA 668.3K
- Earning Date
- ILPT 02-18-2025
- HURA 02-15-2025
- Dividend Yield
- ILPT 1.23%
- HURA N/A
- EPS Growth
- ILPT N/A
- HURA N/A
- EPS
- ILPT N/A
- HURA N/A
- Revenue
- ILPT $440,696,000.00
- HURA N/A
- Revenue This Year
- ILPT N/A
- HURA N/A
- Revenue Next Year
- ILPT $6.87
- HURA N/A
- P/E Ratio
- ILPT N/A
- HURA N/A
- Revenue Growth
- ILPT 1.36
- HURA N/A
- 52 Week Low
- ILPT $3.15
- HURA $2.84
- 52 Week High
- ILPT $5.45
- HURA $14.60
- Technical
- Relative Strength Index (RSI)
- ILPT 35.88
- HURA N/A
- Support Level
- ILPT $3.60
- HURA N/A
- Resistance Level
- ILPT $3.78
- HURA N/A
- Average True Range (ATR)
- ILPT 0.15
- HURA 0.00
- MACD
- ILPT -0.03
- HURA 0.00
- Stochastic Oscillator
- ILPT 18.97
- HURA 0.00
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.